Dr. Wang graduated from Johns Hopkins University with a PhD under the supervision of Dr. Bert Vogelstein at the School of Medicine and earned an MHS in Biostatistics under Dr. Rafael Irizarry at the Bloomberg School of Public Health. He completed his undergraduate and master’s studies in Molecular Biology at Nankai University, where he trained with Dr. Tianhui Zhu, the Founding Dean of Nankai University School of Medicine. In 2023, Dr. Wang also graduated with an MBA degree from The Wharton Business School of the University of Pennsylvania.
Over the past 17 years, Dr. Wang has focused his research on clinical proteomics and genomics. His journey began in 2007 when he joined Dr. Vogelstein’s lab at Johns Hopkins as a PhD student, during which time the lab had just concluded the world’s first cancer genome sequencing. Dr. Wang played a key role in initiating a program for clinical multi-omics analysis of human cancers. By 2010, he had developed the world’s first mutant protein detection and quantification platform, “MT-SRM,” which enabled the precise quantification of protein copy numbers in single human cells using mass spectrometry after NGS-targeted sequencing. He subsequently pioneered “SAFE-SRM,” the first scalable proteomics biomarker discovery and validation platform, launching mass spectrometry-based proteomics into clinical practice. His work has systematically evaluated the benefits and challenges of applying different omics technologies for early cancer detection.
From 2019, Dr. Wang secured over $10 million in venture capital investment from prestigious investors, enabling him to further his pioneering work in molecular diagnostics. In that period, he invented “MANA-SRM” and “Valid-NEO®” pipelines for the direct detection and quantification of neoantigens from tumor cells and minute tissue samples, paving the way for new advancements in personalized cancer therapies. More recently, he developed the Complete360® clinical proteomics diagnostics platform, which enables multi-omics quantification of a broad spectrum of biomarkers in body fluids. In addition, Dr. Wang invented and patented “DEEPER-Seq” the world’s only barcoded single-stranded library and dual RNA probe-based targeted sequencing platform for ultra-rare mutation detection using NGS technology.
His research has been featured in major media outlets such as Genomeweb, Newswire, ScienceDaily, and high-impact peer-reviewed journals.
As the founder of Complete Omics Inc., Dr. Wang continues to push the boundaries of molecular diagnostics, particularly in clinical proteomics, advancing personalized disease management and precision medicine through cutting-edge omics technologies.
